ReviewNature reviews. Immunology2022
Immunobiology and pathogenesis of hepatitis B virus infection.
Review in Nature reviews. Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 282 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
282 citing papers in PubMed, 5 syntheses or guidelines pooled it, 469 citations in OpenAlex.
- Global prevalence of chronic kidney disease and its influencing factors among chronic hepatitis B: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Viral infections and the risk of neurodegenerative diseases: a comprehensive meta-analysis and systematic review.Translational psychiatry · 2025Pooled it
- Pooled it
- Precore mutation enhances viral replication to facilitate persistent infection especially in HBeAg-negative patients.Virologica Sinica · 2024Pooled it
- Autophagy-related genes polymorphism in hepatitis B virus-associated hepatocellular carcinoma: A systematic review.Immunity, inflammation and disease · 2024Pooled it
- Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease.Experimental & molecular medicine · 2026Review
- Functional heterogeneity and plasticity in naïve CD8 T cells drive superior effector and memory responses.The Journal of experimental medicine · 2026Article
- ANKRD11 deficiency reprograms CD8Nature immunology · 2026Article
- Hippuric acid contributes to NK-cell activation with dependence on TLR2 in chronic hepatitis B complicated by MASLD.iScience · 2026Article
- Core protein mutations are key determinants of hepatitis B virus replication during the hepatitis B e antigen-negative stage.The Journal of general virology · 2026Article
- MicroRNA Control of Hepatocyte-Stromal Crosstalk in the Early Premalignant Microenvironment of HBV-Associated HCC.International journal of molecular sciences · 2026Review
- Patient awareness of viral hepatitis infection in Al-Madinah, Saudi Arabia: a cross-sectional study.Scientific reports · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Hepatitis B virus-specific T cell receptor therapy for advanced hepatocellular carcinoma: lessons from WuHepatobiliary surgery and nutrition · 2026Article
- Divergent hepatitis B neutralizing antibody trajectories after spontaneous control in people with and without HIV.Research square · 2026Article
- Liver Macrophages in the Pathogenesis of Viral Hepatitis.Current issues in molecular biology · 2026Review
- Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers.Nature reviews. Immunology · 2026Review
- New Developments in the Treatment of Hepatitis B Virus Infection.Gastroenterology & hepatology · 2026Article
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B.Nature communications · 2026Article
222 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the past four decades, the basic principles of HBV gene expression and replication as well as the viral and host determinants governing infection outcome have been largely uncovered. Whereas HBV appears to induce little or no innate immune activation, the adaptive immune response mediates both viral clearance as well as liver disease. Here, we review our current knowledge on the immunobiology and pathogenesis of HBV infection, focusing in particular on the role of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.